

The logo for Medicilon, featuring the word "MEDICILON" in a white, sans-serif font inside a white oval.

MEDICILON

The logo for EDI ILO, featuring the text "EDI ILO" in a white, sans-serif font next to a small white square.


EDI ILO

美迪西mRNA肿瘤疫苗研发服务平台



mRNA

mRNA



mRNA mRNA mRNA mRNA mRNA

Short research and development cycle

Induce stronger immune responses

Rapid production


The advantages of mRNA vaccines in the context of cancer therapy^[3]

mRNA

-
- mRNA
-
-

mRNA

mRNA 5' (ORF) (UTR) poly(A) 3' mRNA (UTR) mRNA



mRNA

mRNA

- 5' 5'Cap) (m7GpppG) mRNA 5' mRNA
- 5'-UTR 3'-UTR 5'-UTR 3'-UTR mRNA
- (ORF) mRNA
- Poly(A) tail Poly(A) tail 5' cap mRNA
- mRNA

- TLR TLR4 MPLA TLR7 Imiquimod
- STING
- TriMix CD40 CD70 TLR4 mRNA
- (GM-CSF)
- mRNA

mRNA

:

- (LNP) mRNA
- mRNA RNase
- mRNA LNPs mRNA
- (PEI) I- (PLL) (PAMAM) β - (PBAE)
- mRNA (CPPs)
- mRNA TLR7/8
- mRNA / α

A

IFN- γ (CD4⁺)

cell percent(%)

NC PC Peptide

▲ PBS
■ Active control
◆ Peptide-Sug/mouse
▼ Peptide-2.Sug/mouse

B

IFN- γ (CD8⁺)

cell percent(%)

PC Peptide NC

▲ PBS
■ Active control
◆ Peptide-Sug/mouse
▼ Peptide-2.Sug/mouse

mRNA

mRNA

PBMC

TSA

TSA


T

PBMC

TAA

mRNA

mRNA



RNA

mRNA GLP
 $\alpha 1$ $\alpha 2$

mRNA

	0	10	10	5	5
		10	10	5	5
		10	10	5	5

Parameters evaluated: cage-side observation, clinical observation, injection site reaction, body weight, food consumption, ophthalmology exam, serum biochemistry, hematology, coagulation, lymphocyte phenotyping, urinalysis, immunogenicity, C-reactive protein, $\alpha 1$ -acid glycoprotein, $\alpha 2$ -macroglobulin, immunoglobulin, cytokines, complements, bone marrow smear, and histopathology.



mRNA

mRNA

mRNA

mRNA

mRNA


mRNA

mRNA

mRNA

mRNA

- [1]. Yashavantha L Vishweshwaraiah, et al. mRNA vaccines for cancer immunotherapy. *Front Immunol.* 2022 Dec 14;13:1029069. doi: 10.3389/fimmu.2022.1029069.
- [2]. Cathrine Lund Lorentzen, et al. Clinical advances and ongoing trials on mRNA vaccines for cancer treatment. *Lancet Oncol.* 2022 Oct;23(10):e450-e458. doi: 10.1016/S1470-2045(22)00372-2.
- [3]. Bolin Wang, et al. Recent advances in mRNA cancer vaccines: meeting challenges and embracing opportunities. *Front Immunol.* 2023 Sep 6;14:1246682. doi: 10.3389/fimmu.2023.1246682.
- [4]. Youhuai Li, et al. mRNA vaccine in cancer therapy: Current advance and future outlook. *Clin Transl Med.* 2023 Aug;13(8):e1384. doi: 10.1002/ctm2.1384.
- [5]. Yuan Yuan, et al. Advances of mRNA vaccine in tumor: a maze of opportunities and challenges. *Biomark Res.* 2023 Jan 18;11(1):6. doi: 10.1186/s40364-023-00449-w.
- [6]. Youhuai Li, et al. mRNA vaccine in cancer therapy: Current advance and future outlook. *Clin Transl Med.* 2023 Aug;13(8):e1384. doi: 10.1002/ctm2.1384.



marketing@medicilon.com

585

MEDICILON